Equillium, Inc. Profile Avatar - Palmy Investing

Equillium, Inc.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clin…

Biotechnology
US, La Jolla [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Equillium, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of EQ's Analysis
CIK: 1746466 CUSIP: 29446K106 ISIN: US29446K1060 LEI: - UEI: -
Secondary Listings
EQ has no secondary listings inside our databases.